Trends in initial management of prostate cancer in New Hampshire - Abstract

PURPOSE: Prostate cancer management strategies are evolving with increased understanding of the disease.

Specifically, there is emerging evidence that "low-risk" cancer is best treated with observation, while localized "high-risk" cancer requires aggressive curative therapy. In this study, we evaluated trends in management of prostate cancer in New Hampshire to determine adherence to evidence-based practice.

METHODS: From the New Hampshire State Cancer Registry, cases of clinically localized prostate cancer diagnosed in 2004-2011 were identified and classified according to D'Amico criteria. Initial treatment modality was recorded as surgery, radiation therapy, expectant management, or hormone therapy. Temporal trends were assessed by Chi-square for trend.

RESULTS: Of 6,203 clinically localized prostate cancers meeting inclusion criteria, 34, 30, and 28 % were low-, intermediate-, and high-risk disease, respectively. For low-risk disease, use of expectant management (17-42 %, p < 0.001) and surgery (29-39 %, p < 0.001) increased, while use of radiation therapy decreased (49-19 %, p < 0.001). For intermediate-risk disease, use of surgery increased (24-50 %, p < 0.001), while radiation decreased (58-34 %, p < 0.001). Hormonal therapy alone was rarely used for low- and intermediate-risk disease. For high-risk patients, surgery increased (38-47 %, p = 0.003) and radiation decreased (41-38 %, p = 0.026), while hormonal therapy and expectant management remained stable.

DISCUSSION: There are encouraging trends in the management of clinically localized prostate cancer in New Hampshire, including less aggressive treatment of low-risk cancer and increasing surgical treatment of high-risk disease.

Written by:
Ingimarsson JP, Celaya MO, Laviolette M, Rees JR, Hyams ES.   Are you the author?
Section of Urology, Department of Surgery, Dartmouth-Hitchcock Medical Center, Lebanon, NH, USA.  

Reference: Cancer Causes Control. 2015 Apr 4. Epub ahead of print.
doi: 10.1007/s10552-015-0574-8

 
PubMed Abstract
PMID: 25840558

UroToday.com Prostate Cancer Section

E-Newsletters

Newsletter subscription

Free Daily and Weekly newsletters offered by content of interest

The fields of GU Oncology and Urology are rapidly advancing. Sign up today for articles, videos, conference highlights and abstracts from peer-review publications by disease and condition delivered to your inbox and read on the go.

Subscribe